BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
      • Artificial intelligence
    • Coronavirus
    • Israel
    • IVDs on the rise
    • Radiopharmaceuticals
    • Rise of obesity
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 11, 2023
Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
Endocrine/metabolic RSS Feed RSS

Endocrine/Metabolic

Medimmune divulges new dual GCGR/GLP-1R agonists

Aug. 30, 2023
No Comments
Medimmune Ltd. has prepared and tested lipidated peptide analogues with improved stability acting as dual agonists of glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-1R). They are reported to be useful for the treatment of obesity, nonalcoholic steatohepatitis (NASH) and type 2 diabetes.
Read More
Vascular system
Cardiovascular

Eli Lilly presents the preclinical profile of LY-3473329

Aug. 30, 2023
No Comments
Human lipoprotein(a) (Lp(a)) is a lipoprotein complex composed of a low-density lipoprotein (LDL) particle and a large highly polymorphic glycoprotein named apolipoprotein (a) (apo(a)). There is evidence that Lp(a) is linked to cardiovascular disorder risk.
Read More
Test tubes, capsules, dropper
Drug Design, Drug Delivery & Technologies

CCM Biosciences outlines preclinical pipeline on launch

Aug. 30, 2023
No Comments
CCM Biosciences Inc. has launched with a focus on discovering and developing novel drugs, including small molecules, gene therapies, biologics and nanomedicines, and companion diagnostic tests.
Read More
Colorful illustration of the heart
Endocrine/Metabolic

AT-02, a humanized IgG1-peptide fusion reagent that potently binds cardiac amyloid

Aug. 30, 2023
No Comments
At the recent ESC Congress, researchers from University of Tennessee and Attralus Inc. presented preclinical data on the novel pan-amyloid-binding peptide fusion immunoglobulin AT-02, which is being developed for the treatment of amyloidosis.
Read More
Hear with tape measure
Endocrine/Metabolic

A novel NLRP3 inhibitor reverses the cardiometabolic impact of obesity in models

Aug. 24, 2023
No Comments
Obesity is known to be associated with metabolic and cardiovascular disorders such as insulin resistance, type 2 diabetes, hypertension, or heart failure, all presenting a chronic low-grade inflammatory component. The activation of the NLRP3 inflammasome pathway appears to be linked to the development of cardio-metabolic diseases.
Read More
Illustration of pancreas, close up of islet
Endocrine/Metabolic

Abata Therapeutics selects ABA-201 Treg cell therapy as development candidate for type 1 diabetes

Aug. 24, 2023
No Comments
Abata Therapeutics Inc. has announced its second development candidate, ABA-201, which has the potential to be a disease-modifying Treg cell therapy for patients with type 1 diabetes who have remaining β cell function. Abata expects to begin clinical studies in 2025.
Read More

Innovent scores first approval for PCSK9 inhibitor in China

Aug. 22, 2023
By Tamra Sami
No Comments
China’s National Medical Products Administration has approved Innovent Biologics Inc.’s proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitor, Sintbilo (tafolecimab), making it the first first locally developed PCSK9 monoclonal antibody to be approved in China.
Read More
Endocrine/Metabolic

Gasherbrum Bio discovers new GLP1R agonists

Aug. 21, 2023
No Comments
Gasherbrum Bio Inc. has described glucagon-like peptide 1 receptor (GLP1R) agonists reported to be useful for the treatment of type 2 diabetes, dyslipidemia, hyperglycemia, hypertension, obesity, stroke, myocardial infarction and gout, among others.
Read More
3D rendering showing osteoporosis in the femur
Musculoskeletal

Osteoporosis target gene CD109 identified by convergent analyses

Aug. 18, 2023
No Comments
Researchers working at the Lady Davis Institute, Jewish General Hospital, McGill University, have combined whole-exome sequencing (WES) from nearly 300,000 samples from the multiancestry UK Biobank, with ultrasound-derived heel estimated bone mineral density (eBMD) and genome-wide association (GWAS) data to identify potential future therapeutic targets for patients with osteoporosis.
Read More

Innovent scores first approval for PCSK9 inhibitor in China

Aug. 17, 2023
By Tamra Sami
No Comments
China’s National Medical Products Administration has approved Innovent Biologics Inc.’s proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitor, Sintbilo (tafolecimab), making it the first first locally developed PCSK9 monoclonal antibody to be approved in China. The approval is for treatment of adult patients with primary hypercholesterolemia (including heterozygous familial and non-familial hypercholesterolemia) and mixed dyslipidemia (abnormal lipid levels). Tafolecimab marks Innovent's first cardiovascular drug as well as the company’s 10th approval.
Read More
Previous 1 2 … 5 6 7 8 9 10 11 12 13 … 1747 1748 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 8, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for December 8, 2023.
  • Coronavirus, mRNA and syringe

    Off-target immune response from modified mRNA impacts future development

    BioWorld
    The Nobel Prize-winning modification that prevents the innate immune system from recognizing injected mRNA as foreign and blocking transcription of the protein it...
  • Stock chart with falling red arrow

    ‘Ridiculous’ site-based hitches mar Biovie phase III in Alzheimer’s

    BioWorld
    For the second time this week, a contract research organization has come under fire for trial-conduct issues – criticism leveled most recently by Biovie Inc.,...
  • Feet and scale

    Waging the losing battle: Altimmune takes on challengers as Pfizer falls back

    BioWorld
    Altimmune Inc.’s peptide-based glucagon-like peptide-1/glucagon dual receptor agonist pemvidutide hiccupped in a phase I study earlier this year but has bounced...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing